NK9.F Neuren Pharmaceuticals Limited

Healthcare Biotechnology Frankfurt Exchange
14.30 EUR
Close of Nov 12, 2026
6.35 14.70
Market cap
EUR 1.81B
P/E
158.9x
P/B
9.00x
ROE
9.0%
Dividend yield
1.27%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NK9.F undervalued?

Graham number

The Graham number of Neuren Pharmaceuticals Limited cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuren Pharmaceuticals Limited fundamental analysis

No fundamental analysis for Neuren Pharmaceuticals Limited yet.

Neuren Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial…

Full company profile